جست‌وجوی استاد و پژوهشگر

Jalees Rehmanمشاهده پروفایل

استاد

• Cardiology
• Inflammation
• Lung Infection
• +۵ مورد دیگر

Dr. Jalees Rehman serves as Professor of Medicine and Pharmacology and Head of the Department of Biochemistry and Molecular Genetics at the University of Illinois Chicago College of Medicine. His leadership spans institutional administration and cutting-edge biomedical research focused on vascular injury mechanisms. His research expertise encompasses: Organ-specific blood vessel vulnerability (particularly lung vasculature in severe infections) Modulation of inflammatory responses to prevent tissue damage Stem cell-mediated tissue regeneration pathways Machine learning applications for gene regulation analysis in injury/repair processes Recent research trends demonstrate strong integration of computational approaches with vascular biology, particularly in understanding: COVID-19-related vascular complications Post-viral neurological disorders Cancer-associated vascular dysfunction No scientific awards are documented in available sources. His laboratory actively trains graduate students through the Graduate Education in Biomedical Sciences (GEMS) program, particularly within the Cell Biology and Regenerative Medicine concentration. Research is supported by NIH funding within the top-ranked Pharmacology and Regenerative Medicine department. Dr. Rehman's laboratory focuses on vascular injury mechanisms in bacterial/viral infections, utilizing both experimental models and computational tools to identify therapeutic targets for tissue protection and regeneration.

• Tumor microenvironment
• Macrophage biology
• Hypoxia inducible factor (HIF) biology
• +۶ مورد دیگر

Dr. Timothy Eubank is a Professor in the Department of Microbiology, Immunology & Cell Biology at West Virginia University School of Medicine. He also serves as a Senior Advisor at the WVU Health Sciences Center in the Department of Research & Graduate Education and is a Member of the WVU Cancer Institute Research Programs. Dr. Eubank's research focuses on the role of myeloid cells and mononuclear phagocytes in tumor growth and angiogenesis, with particular expertise in monocyte and macrophage HIF (hypoxia inducible factor) biology. His lab has made several groundbreaking discoveries, including being the first to report that GM-CSF stimulates tumor macrophages to overexpress soluble VEGFR-1, which sequesters tumor-produced VEGF, and the first to identify the disparate functions of HIF-1α and HIF-2α in tumor-associated macrophages, discovering that HIF-2α can be anti-angiogenic. Analysis of Dr. Eubank's recent publications reveals a strong focus on tumor microenvironment, particularly examining macrophage subsets in breast and pancreatic cancers using advanced Electron Paramagnetic Resonance (EPR) imaging techniques. His work spans multiple disciplines including cancer biology, immunology, biomedical engineering, and molecular imaging, with a consistent theme of understanding how tumor hypoxia and immune cell interactions drive cancer progression. K99/R00 Pathway to Independence Award from the National Cancer Institute Dr. Eubank's research is supported by multiple collaborations across WVU, working with colleagues in Biochemistry, Pharmaceutical Sciences, Radiology, and Surgery to develop novel molecular probes for in vivo measurement of tumor oxygenation, pH, and inorganic phosphate. His lab's work on understanding how different macrophage HIFs regulate chemotherapy success in breast cancer models has significant implications for improving cancer treatment efficacy. Dr. Eubank's lab occupies spaces 5612, 5608, 5607, and 5602 in the Health Sciences South building, where his team conducts research on the 'In vivo Multifunctional Magnetic Resonance Research' program, investigating the origin and role of macrophages that initiate and maintain treatment resistance in breast and pancreatic cancers.

Mamta Amruteمشاهده پروفایل

دانشیار

• Molecular motor proteins
• Hypertrophic cardiomyopathy
• Single molecule biophysics
• +۵ مورد دیگر

Dr. Mamta Amrute is an Associate Professor and Principal Investigator at the Institute of Molecular and Cell Physiology, Hannover Medical School (MHH), where she has led her research group since 2017. Her academic journey includes a PhD from MHH (2003-2006), postdoctoral research at MHH (2012-2016), and at the prestigious Medical Research Council-Laboratory of Molecular Biology in Cambridge, UK (2008-2011). Her research program focuses on single-molecule biophysics of molecular motor proteins , with particular emphasis on understanding how mutations in cardiac myosin lead to hypertrophic cardiomyopathy (HCM), a condition affecting approximately 1 in 200 individuals worldwide. The lab employs advanced techniques including Total Internal Reflection Fluorescence Microscopy, optical trapping, and zero-mode waveguides to investigate fundamental motor protein mechanisms. Analysis of recent publications reveals three major research trajectories: 1) Detailed characterization of cardiac and skeletal myosin isoforms at the single-molecule level, 2) Investigation of epigenetic regulation in muscle physiology and atrophy, and 3) Development of computational tools for biochemical research. This work has significant implications for understanding and potentially treating heart disease and muscle wasting conditions. Dr. Amrute's research is supported by multiple funding sources including the Deutsche Forschungsgemeinschaft (DFG), Fritz Thyssen Foundation, and MHH's early career research grant program (HilF). She supervises a diverse team of doctoral students and postdoctoral researchers, providing training in advanced biophysical techniques. The Amrute-Nayak Research Group maintains an extensive international collaboration network spanning institutions in the UK, USA, Japan, Italy, Sweden, and Australia, facilitating cross-disciplinary approaches to studying molecular motors and muscle diseases. Her work bridges fundamental biophysics with clinical applications in cardiology and muscle physiology.

Espen Spangenburgمشاهده پروفایل

استاد

• Skeletal Muscle Physiology
• Endocrine Regulation
• Metabolic Function
• +۵ مورد دیگر

Dr. Espen Spangenburg is a Professor and Chair in the Department of Anatomy and Cell Biology at the Brody School of Medicine, East Carolina University, where he also holds an appointment at the East Carolina Diabetes and Obesity Institute (ECDOI). Previously, he served as an Associate Professor in the Department of Physiology at the same institution (2015-2021), and held faculty positions at the University of Maryland (2006-2015) and UC Davis (2003-2006). Dr. Spangenburg's research program focuses on understanding the endocrine-based regulation of physiological and metabolic function of skeletal muscle. His lab employs an integrative experimental approach, using cell culture and animal models to define mechanisms that they then translate to human physiology. They have developed skeletal muscle-specific inducible BRCA1 and ER-alpha knock out mice and techniques to ablate these genes in cultured human myotubes. The lab has pioneered methods to measure force, mitochondrial function, deliver cDNA, and image organelles in single muscle fibers. His publication record includes over 120 peer-reviewed articles with an h-index of 52 and more than 8,221 total citations, including 19 papers cited over 100 times. His most recent work continues to explore skeletal muscle metabolism, mitochondrial function, and endocrine regulation, with publications in high-impact journals including Cell Metabolism, Diabetes, and Circulation. Selected Awards: 2014 Leda Amick Wilson UMD Mentor of the Year Award 2011 Best Paper Award UMD School of Public Health Research Interaction Day 2010 Virginia Tech HNFE Outstanding Alumnus Award 2008-2014 NIH Loan Repayment Grant Recipient Dr. Spangenburg serves on multiple editorial boards including American Journal of Physiology: Cell Physiology and Journal of Applied Physiology. He has been an active NIH study section member since 2015 and has received continuous research funding from NIH and the American Diabetes Association for his work on skeletal muscle function and metabolism. His lab maintains an active research program investigating the role of BRCA1 and estrogen receptor signaling in skeletal muscle function, with current projects examining how these pathways regulate mitochondrial function and protect against metabolic disease.

• Genome Editing
• CRISPR Technologies
• Neuromuscular Diseases
• +۶ مورد دیگر

Christiano Alves, PhD is an Assistant Professor in the Department of Pathology at the University of Pittsburgh, specifically within the Division of Experimental Pathology. His research program integrates cutting-edge genome editing technologies with applied physiology to develop novel therapies for neuromuscular and metabolic diseases. Dr. Alves received his BS and PhD from the University of Sao Paulo, Brazil, completing his doctoral studies in 2017. He then completed postdoctoral training at Harvard Medical School and Massachusetts General Hospital, where he worked at the Joslin Diabetes Center on projects related to exercise and metabolism, and later at the Center for Genomic Medicine focusing on neuromuscular diseases and CRISPR technologies under the mentorship of Dr. Benjamin Kleinstiver. His research interests lie at the intersection of genome editing and applied physiology, with a specific focus on developing treatments for neurodegenerative conditions including Amyotrophic Lateral Sclerosis (ALS) and spinal muscular atrophy (SMA). The Alves Lab leverages expertise in molecular metabolism and muscle biology to optimize genome editing approaches for therapeutic applications. Genome Editing and CRISPR Technologies Neuromuscular Diseases Neurodegenerative Disorders Metabolic Diseases Therapeutic Development Translational Medicine Dr. Alves has established an active research program with multiple publications in high-impact journals, focusing on the development and optimization of base editing technologies for treating genetic disorders. His work demonstrates a strong trajectory in advancing genome editing approaches toward clinical applications for severe diseases. As a recently appointed independent investigator, Dr. Alves is building a research team focused on pushing the boundaries of genome editing therapeutics. His lab combines physiological expertise with advanced gene editing techniques to address significant unmet medical needs in neurodegenerative conditions. The Alves Lab is actively seeking motivated students and postdoctoral researchers interested in genome editing, neuromuscular diseases, and translational research. Prospective trainees should have a strong foundation in molecular biology and an interest in developing innovative therapeutic approaches for severe diseases.

• Medicinal Chemistry
• Cancer Research
• Virology
• +۴ مورد دیگر

LUNG Hong Lok serves as an Assistant Professor in the Department of Chemistry at Hong Kong Baptist University's Faculty of Science, specializing in oncology-focused medicinal chemistry research targeting nasopharyngeal carcinoma (NPC) and related cancers. His core research domains include: Development of anti-Epstein-Barr virus (EBV) inhibitors and NPC imaging agents Cancer immunology, cachexia, and metabolic pathways in NPC Tumor metastasis mechanisms of NPC Therapeutic target identification using normal/cancer organoid models Drug screening for NPC and esophageal squamous cell carcinoma No scientific awards were documented in the provided source material. Details regarding graduate student supervision, research funding, or laboratory infrastructure were not disclosed in the available text.

Patricia A Robinsonمشاهده پروفایل

دانشیار

• Breast Cancer Research
• Immunotherapy
• Metastatic Breast Cancer
• +۲ مورد دیگر

Associate Professor in the Department of Medicine, Division of Hematology and Oncology at Northwestern University Feinberg School of Medicine. Specializes in breast cancer research with focus on metastatic disease, immunotherapy, and nutritional impacts on outcomes. Affiliated with the Robert H. Lurie Comprehensive Cancer Center. Education: Board Certified in Medical Oncology, Northwestern University Research centers on breast cancer subtypes , particularly hormone receptor-positive and triple-negative metastatic disease. Investigates immune biomarkers for immunotherapy response, body composition impacts on survival, and nutritional interventions like vitamin D supplementation. Leads clinical trials exploring novel neoadjuvant combinations including immunotherapy and metabolic agents. Current leadership roles include Co-chair of Big Ten Cancer Research Consortium (breast focus), advisor to SWOG Vice Chair for Diversity, Equity and Inclusion, and President of Equal Hope. Serves on NCCN-Pfizer metastatic breast cancer project and previously chaired Education Committee. Professional Affiliations: American Society of Clinical Oncology (1999-Present) Southwest Oncology Group (SWOG) (2023-Present) Cancer Support Community (2013-Present) Principal Investigator for active clinical trials including SWOG 2206 (durvalumab + chemotherapy for MammaPrint Ultrahigh breast cancer). Industry collaborations include Merck & Co. and Pfizer for educational activities.

Richard L Lieberمشاهده پروفایل

استاد

• Skeletal Muscle Physiology
• Biomechanics
• Orthopaedic Surgery
• +۷ مورد دیگر

Richard L Lieber, PhD, MBA, is a Professor of Physical Medicine and Rehabilitation and Neuroscience at Northwestern University's Feinberg School of Medicine. He serves as Chief Scientific Officer and Senior Vice President of the Shirley Ryan AbilityLab and is a Senior Research Career Scientist at the Edward Hines, Jr., VA Hospital in Hines, Illinois. Dr. Lieber joined the Shirley Ryan AbilityLab (formerly Rehabilitation Institute of Chicago) in 2014 and oversees more than 200 researchers and over 150 research studies and clinical trials. Dr. Lieber earned his PhD in Biophysics from the University of California, Davis in 1983 and his MBA from the University of California, San Diego in 2013. His research focuses on the design and plasticity of skeletal muscle, with particular emphasis on muscle contracture in neurological conditions such as cerebral palsy, stroke, and spinal cord injury. Dr. Lieber has published over 386 scientific articles spanning from fundamental research in journals like The Biophysical Journal and The Journal of Cell Biology to clinical applications in The Journal of Hand Surgery and Clinical Orthopaedics and Related Research. His recent work demonstrates trends in human muscle physiology, rehabilitation assessment tools, and the development of innovative measurement techniques for muscle function across various patient populations including those with spinal cord injury, cerebral palsy, and cancer-related conditions. Paul B. Magnuson Award from the U.S. Department of Veterans Affairs (2023) Elsass Foundation Research Prize in Cerebral Palsy (2023) Kappa Delta Award, American Academy of Orthopedic Surgeons (2013) Giovanni Borelli Award, American Society of Biomechanics (2007) Lifetime Achievement Award from American Academy for Cerebral Palsy and Developmental Medicine (2021) Dr. Lieber manages a grant portfolio exceeding $152 million from major agencies including NIH, VA, DoD, and NIDILRR. He leads the implementation of the "Research Accelerator Program" at Shirley Ryan AbilityLab, enabling translational research with nearly 200 non-research staff. He also designed the Biologics Lab, the only rehabilitation-setting lab of its kind in the world, bringing together biologists, physiologists, and molecular biologists to accelerate discoveries in rehabilitation science. As Chief Scientific Officer, Dr. Lieber oversees all research endeavors throughout the Shirley Ryan AbilityLab system of care and has pioneered studies of human muscle during hand surgery and in conditions of muscle contracture. His laboratory has been continuously supported by the National Institutes of Health for over 40 years.

Andreas Bergthalerمشاهده پروفایل

استاد

• Immunology
• Infectious Diseases
• Cancer Biology
• +۷ مورد دیگر

Professor Andreas Bergthaler leads the Bergthaler Lab at the Medical University of Vienna and serves as an Adjunct Principal Investigator at CeMM (Research Center for Molecular Medicine of the Austrian Academy of Sciences). His research bridges immunology , virology , and metabolism , focusing on systemic immunometabolism, pathogen surveillance, and transmissible cancers. Doctorate in Veterinary Medicine, University of Veterinary Medicine Vienna PhD, ETH Zurich & University of Zurich Postdoc, University of Geneva & Institute for Systems Biology His work explores: Multi-organ crosstalk in cachexia during chronic infections Pathogen surveillance in wastewater and air filters Immune evasion in transmissible cancers Viral persistence and CD8+ T cell dysfunction Recent publications highlight advances in: 2025: Gut - Metabolic targeting of intestinal inflammation 2025: EMBO Mol Med - EGFR signaling in colorectal cancer 2024: Nat Metab - Single-cell immunometabolism tools Recognized with: ERC Starting Grant Loffler-Frosch Prize (Society of Virology) He co-founded Hookipa Pharma, developing immunotherapies for infections and cancers, and collaborates across epidemiology , neurobiology , and public health .

• Cardiology
• Heart Failure
• Cardiovascular Physiology
• +۶ مورد دیگر

Rajiv Sankaranarayanan is an Honorary Senior Clinical Lecturer at the University of Liverpool's Liverpool Centre for Cardiovascular Science and a Consultant Cardiologist at Liverpool University Hospitals NHS Foundation Trust. He also serves as a Research Scholar at the National Institute for Health Research in Liverpool. His educational background includes a PhD in Cardiovascular Physiology from the University of Manchester (2011-2014), an MBBS from Bangalore Medical College and Research Institute (1996-2001), and prestigious qualifications including Fellowship of the Heart Failure Association, FRCP from both the Royal College of Physicians and the European Society of Cardiology. Dr. Sankaranarayanan's research focuses on heart failure, particularly in areas of iron deficiency management, digital health applications, and the intersection of cardiovascular disease with conditions like sarcopenia and frailty. His work often involves clinical trials such as the IRONMAN study and community-based screening initiatives like the BEAT-HF tool. His extensive publication record demonstrates significant contributions to understanding heart failure treatment, risk prediction models, and innovative approaches to cardiac care delivery through virtual wards and telehealth platforms. Fellowship of Heart Failure Association (FHFA) FRCP (Royal College of Physicians) FRCP (European Society Of Cardiology) NIHR Research Scholarship Dr. Sankaranarayanan has received significant research funding, including a British Heart Foundation grant (FS/11/15/28693) for his PhD work on cardiac physiology, European Society of Cardiology funding for cellular electrophysiology research, and NHSX funding for the End to End Digital Heart Failure Pathway project. His work with the Liverpool heart failure virtual ward model represents a major initiative in outpatient management of acute heart failure. He is actively involved with the British Cardiovascular Society, having participated in their Emerging Leadership Program from 2019-2022, and continues to contribute to advancing cardiovascular care through multiple collaborative research projects.

• Nutrigenomics
• Cancer Research
• Diet and Disease
• +۴ مورد دیگر

Svanhild Margrethe Arentz Schønberg serves as Department Head at the Department of Health Sciences Ålesund within the Faculty of Medicine and Health Sciences at the Norwegian University of Science and Technology (NTNU). With a distinguished career spanning over 30 years, she leads research at the intersection of nutrition science and cancer biology. Her academic foundation includes a Cand.Scient. in Chemistry (1989) from the University of Trondheim and a Doctor Scientiarum in Biochemistry (1997) from NTNU. Her research program focuses on nutrigenomics and cancer metabolism , particularly investigating how omega-3 polyunsaturated fatty acids influence cancer cell behavior. Key interests include: Molecular mechanisms of DHA/EPA in colon cancer models Cancer cachexia and nutritional interventions ER stress and autophagy pathways in fatty acid-induced cytotoxicity Translational applications for enhancing conventional cancer therapies Analysis of her 15 most recent publications reveals consistent focus on colorectal cancer models with strong emphasis on molecular mechanisms (ER stress, autophagy), translational applications (chemotherapy enhancement), and nutritional interventions (omega-3 fatty acids). Her work bridges basic science and clinical applications, with increasing focus on patient-derived models and palliative care contexts in recent years. As Department Head and active researcher, she maintains robust supervision of doctoral candidates and postdocs. Current projects include: Translational Research in Lung Cancer and Palliative Care (TLCPC) EPCRC consortium on symptom management Salmon oil chemotherapeutic potential studies Her laboratory serves as a hub for nutrigenomics research at NTNU's Ålesund campus, providing state-of-the-art facilities for molecular oncology studies while fostering collaborations across clinical and basic science domains. The research environment emphasizes both technical excellence and translational impact, preparing students for diverse careers in academic medicine and pharmaceutical research.

Vandré Figueiredoمشاهده پروفایل

استادیار

• Skeletal Muscle Physiology
• Muscle Metabolism
• Ribosome Biogenesis
• +۴ مورد دیگر

Vandré Figueiredo serves as an Assistant Professor in the Department of Biological Sciences at Oakland University. His office is located in Dodge Hall room 303, with laboratory facilities in rooms 310 and 312. He teaches advanced courses including BIO 4620/5620 Advanced Human Physiology and maintains an active research program focused on skeletal muscle physiology. Dr. Figueiredo's research centers on skeletal muscle's role in whole-body metabolism, health, and longevity. His primary interest lies in understanding the cellular and molecular mechanisms that determine muscle mass during hypertrophy and atrophy. His work specifically investigates ribosome biogenesis and degradation in myofibers, and how these processes impact ribosome homeostasis, protein synthesis, and ultimately muscle size. His laboratory aims to translate these findings into new therapeutic strategies for muscle atrophy conditions including limb immobilization, bed rest, sarcopenia, and cancer cachexia. Analysis of Dr. Figueiredo's recent publications reveals a consistent focus on ribosome dynamics in skeletal muscle. His work spans molecular mechanisms of ribosome regulation, exercise physiology, aging-related muscle decline, and cancer-associated wasting conditions. The interdisciplinary nature of his research bridges molecular biology, physiology, gerontology, and oncology, with particular emphasis on translational applications for clinical conditions involving muscle loss. Dr. Figueiredo maintains an active research laboratory (Figueiredo Lab) with facilities in Dodge Hall. His research program appears to be well-integrated with collaborative networks, as evidenced by co-authorship with researchers from multiple institutions across his publications. While specific grant information isn't provided in the available materials, his ongoing research output suggests active funding support for his laboratory investigations.

Michael X. Zhuمشاهده پروفایل

استاد

• Ion channels
• Calcium signaling
• TRP channels
• +۵ مورد دیگر

Dr. Michael X. Zhu is a Professor at The University of Texas Health Science Center at Houston with extensive expertise in ion channel research and calcium signaling. His academic background includes a Ph.D. from the University of Houston (1991), an M.S. from the University of Houston (1988), and postdoctoral training at Baylor College of Medicine (1994). Dr. Zhu's research focuses on the molecular mechanisms of ion channels, particularly Transient Receptor Potential (TRP) channels and two-pore channels (TPCs). His work has significantly advanced understanding of calcium signaling pathways in cellular physiology. He has made seminal contributions to the field, including the cloning and characterization of TRPC channels and the identification of TPCs as NAADP receptors in endolysosomal membranes. Analysis of Dr. Zhu's recent publications (2020-2022) reveals a strong focus on calcium signaling mechanisms, with particular emphasis on TRP channels and their roles in neuronal function, pain sensation, and disease processes. His work spans multiple disciplines including neuroscience, molecular pharmacology, and cell biology, demonstrating an integrative approach to understanding complex cellular signaling pathways. Dr. Zhu's research program addresses fundamental questions in cellular physiology with implications for understanding and treating various diseases, including neurological disorders, pain conditions, and metabolic diseases. His laboratory combines molecular, pharmacological, and physiological techniques to elucidate the mechanisms of ion channel function and regulation.

• Sociology of Food
• Human-Animal Relationships
• Animal Ethics
• +۷ مورد دیگر

Thomas Bøker Lund serves as an Associate Professor in the Department of Food and Resource Economics at the University of Copenhagen's Faculty of Science, specifically within the Section for Consumption, Bioethics and Governance. His academic journey began with research assistant positions at Copenhagen Business School and the Royal Veterinary and Agricultural University before progressing through a PhD program and ultimately securing his current position in 2017. Lund's research program spans three interconnected domains: 1) Sociology of food examining Nordic eating patterns, meat consumption dynamics, and organic food systems; 2) Human-animal relationships with focus on pet ownership and animal ethics; and 3) Empirical ethics in biotechnology applications including AI in healthcare and genetic technologies in livestock. His methodological approach integrates both qualitative (interviews, focus groups, ethnography) and quantitative (questionnaire) research techniques, allowing for comprehensive exploration of complex socio-ethical issues. His recent publication record demonstrates a clear trajectory toward increasingly interdisciplinary work bridging veterinary science, sociology, and environmental studies. The 2024-2025 publications reveal particular emphasis on human-animal relationships (accounting for approximately 60% of recent work), sustainable food systems (25%), and biotechnology ethics (15%). This pattern reflects growing societal concerns about animal welfare, sustainable food production, and ethical implications of emerging technologies. Lund has supervised 18 graduate students (12 master's thesis and 6 PhD students) and taught multiple courses including Sociology of Food Consumption, Empirical Methods in Social Sciences, and Health, Nutrition and Quality of Life. His teaching portfolio demonstrates commitment to both theoretical foundations and practical research methods in social sciences. His research collaborations span multiple countries with particular strength in UK, Austria, and Denmark partnerships. The visibility of his work is evidenced by media coverage (appearing in 8 news outlets) and significant academic engagement (31 readers on Mendeley for some publications).

Lykke Sylowمشاهده پروفایل

دانشیار

• Molecular Physiology
• Cancer Metabolism
• Ageing Research
• +۳ مورد دیگر

Lykke Sylow is an Associate Professor at the Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen. She leads the research group "Molecular Metabolism in Cancer and Ageing" and has been enrolled in the UCPH professor promotion program since 2022. Her educational background includes: PhD in Molecular Physiology (2014), University of Copenhagen MSc Human Physiology (2010), University of Copenhagen BSc Exercise Biology (2007), University of Copenhagen BSc Psychology (2006), University of Copenhagen and University of Canterbury, NZ Dr. Sylow's primary research focuses on molecular physiology , particularly examining the intersection of metabolism, cancer, and ageing processes. Her work investigates how skeletal muscle metabolism adapts to various stressors including exercise, temperature changes, and disease states. She employs molecular techniques to understand cellular signaling pathways that regulate metabolic homeostasis, with particular emphasis on AMPK signaling, Rac1-mediated adaptations, and mitochondrial function in both healthy and pathological conditions. Her recent publications demonstrate a strong focus on understanding how environmental factors like temperature and diet impact metabolic responses in cancer and obesity models. Her research bridges basic molecular mechanisms with physiological outcomes, often using mouse models to investigate tissue-specific adaptations. The work spans multiple disciplines including endocrinology, exercise physiology, cancer biology, and metabolic disorders. Dr. Sylow has received numerous prestigious awards recognizing her contributions to medical research: Anders Jahre Award for young medical researchers (2022) Erhoff Talent Prize (2021) Bagger-Sørensen Fondens Ung Forskerpris (2021) Danish Diabetes Academy Young Investigator Award (2020) Sapere Aude Research Talent grant (2014) UCPH's Gold medal for Prize essay (2011) She serves on the International Research Group on Biochemistry of Exercise, which organizes the International Biochemistry of Exercise Conference (IBEC), and is a member of the Danish Young Academy under the Royal Academy (2021-2026). Her editorial experience includes a Fellowship on the Journal of Physiology Editorial Board (2020-2022). Dr. Sylow has also been actively involved in promoting gender equality in science through her representation at the UCPH SCIENCE council. As leader of the "Molecular Metabolism in Cancer and Ageing" research group, Dr. Sylow oversees a team investigating the molecular mechanisms connecting metabolism with cancer progression and age-related physiological decline. Her laboratory employs a range of techniques from molecular biology to whole-animal physiology to address fundamental questions about metabolic regulation in health and disease.